

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

Attachment 1
October 8, 2026

【Therapeutic category】 Agents affecting metabolism, n.e.c. (not elsewhere classified)

【Non-proprietary name】 Anamorelin hydrochloride

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)		
Patients receiving the following drugs: Clarithromycin, itraconazole, voriconazole, preparations containing ritonavir, preparations containing cobicistat, ensitrelvir fumaric acid, ceritinib			Patients receiving the following drugs: Clarithromycin, itraconazole, voriconazole, <u>posaconazole</u> , preparations containing ritonavir, preparations containing cobicistat, ensitrelvir fumaric acid, ceritinib		
10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Clarithromycin	The blood	The metabolism of	Clarithromycin	The blood	The metabolism of
Itraconazole	concentration of this	this drug is	Itraconazole	concentration of this	this drug is
Voriconazole	drug may increase,	suppressed due to	Voriconazole	drug may increase,	suppressed due to
Preparations containing	which may lead to	strong CYP3A4	<u>Posaconazole</u>	which may lead to	strong CYP3A4

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

ritonavir Preparations containing cobicistat Ensitrelvir fumaric acid Ceritinib	an increased occurrence of adverse reactions.	inhibition by these drugs.	Preparations containing ritonavir Preparations containing cobicistat Ensitrelvir fumaric acid Ceritinib	an increased occurrence of adverse reactions.	inhibition by these drugs.
---	---	-------------------------------	--	---	-------------------------------

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.